Emergent BioSolutions's quarterly market cap
increased
from Sep. 2025 (€394.6 Mil) to Dec. 2025 (€532.7 Mil) but then
declined
from Dec. 2025 (€532.7 Mil) to Mar. 2026 (€370.6 Mil).
Emergent BioSolutions's annual market cap
increased
from Dec. 2023 (€114.6 Mil) to Dec. 2024 (€421.2 Mil) and
increased
from Dec. 2024 (€421.2 Mil) to Dec. 2025 (€532.7 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Emergent BioSolutions's Enterprise Value for Today is €738.1 Mil.
Emergent BioSolutions (STU:ER4) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:ER4 vs ELTP, NIKA, EOLS: Market Cap Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Emergent BioSolutions's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Emergent BioSolutions Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Emergent BioSolutions's Market Cap distribution charts can be found below:
* The bar in red indicates where Emergent BioSolutions's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Emergent BioSolutions's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Emergent BioSolutions (STU:ER4) has a Market Cap of €375.1 Mil as of Jul. 02, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Emergent BioSolutions and its competitors. According to the industry distribution chart, Emergent BioSolutions ranks #417 out of 1024 companies in the Drug Manufacturers industry, placing it in the top 40.7%.
Is Emergent BioSolutions' Market Cap too high?
Emergent BioSolutions' current Market Cap is €375.1 Mil. Based on the distribution chart, Emergent BioSolutions ranks #417 out of 1024 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Emergent BioSolutions has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Emergent BioSolutions' Market Cap compare to ELTP and NIKA?
According to the Drug Manufacturers industry distribution chart, Emergent BioSolutions ranks #417 out of 1024 companies for Market Cap. This puts Emergent BioSolutions in the upper half of its industry. The industry median Market Cap is 212.74. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 212.74, based on 1,024 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Emergent BioSolutions and its competitors. For the Drug Manufacturers industry, the median Market Cap is 212.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Emergent BioSolutions's current Market Cap is €375.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emergent BioSolutions stock overvalued right now?
Based on GuruFocus' analysis, Emergent BioSolutions (STU:ER4) is currently considered Significantly Overvalued. The stock's GF Value™ is €4.19, compared to a current price of €7.35 — trading 75.3% above its estimated fair value. The current Market Cap is €375.1 Mil. Emergent BioSolutions' overall GF Score™ is 57/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Emergent BioSolutions (STU:ER4), the current Market Cap is €375.1 Mil as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Emergent BioSolutions (STU:ER4) Overvalued in 2026?
Based on GuruFocus' analysis, Emergent BioSolutions stock appears to be overvalued.
The current stock price of €7.35 is trading 75.3% above its estimated GF Value™ of €4.19.
GuruFocus considers Emergent BioSolutions to be Significantly Overvalued.
Key valuation signals for STU:ER4:
Market Cap: €375.1 Mil
GF Value™: €4.19 vs. price of €7.35 (75.3% above fair value)
No single metric tells the full story. See the STU:ER4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
57GF Score
Get the complete analysis for STU:ER4
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:ER4 has been successfully added to your 
